Analysts Set Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Target Price at $5.17

Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) have received an average rating of “Moderate Buy” from the six ratings firms that are presently covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $5.17.

SGMO has been the topic of a number of research analyst reports. Truist Financial lowered their target price on Sangamo Therapeutics from $7.00 to $5.00 and set a “buy” rating on the stock in a report on Thursday, January 23rd. Barclays lifted their target price on Sangamo Therapeutics from $3.00 to $9.00 and gave the stock an “overweight” rating in a report on Thursday, November 14th. Wells Fargo & Company lowered their target price on Sangamo Therapeutics from $3.00 to $2.00 and set an “equal weight” rating on the stock in a report on Tuesday, December 31st. HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price on shares of Sangamo Therapeutics in a report on Monday, January 27th. Finally, Jefferies Financial Group lowered their target price on Sangamo Therapeutics from $7.00 to $3.00 and set a “buy” rating on the stock in a report on Tuesday, December 31st.

Hedge Funds Weigh In On Sangamo Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. E Fund Management Co. Ltd. acquired a new position in shares of Sangamo Therapeutics in the 4th quarter valued at $25,000. JPMorgan Chase & Co. boosted its position in shares of Sangamo Therapeutics by 679.5% in the 4th quarter. JPMorgan Chase & Co. now owns 25,000 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 21,793 shares during the period. PNC Financial Services Group Inc. boosted its position in Sangamo Therapeutics by 2,319.1% during the 4th quarter. PNC Financial Services Group Inc. now owns 26,078 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 25,000 shares during the period. SBI Securities Co. Ltd. acquired a new stake in Sangamo Therapeutics during the 4th quarter worth about $28,000. Finally, Shelton Wealth Management LLC acquired a new stake in Sangamo Therapeutics during the 4th quarter worth about $29,000. Institutional investors and hedge funds own 56.93% of the company’s stock.

Sangamo Therapeutics Stock Performance

Shares of SGMO opened at $0.96 on Wednesday. The firm has a market capitalization of $199.49 million, a price-to-earnings ratio of -1.27 and a beta of 1.30. Sangamo Therapeutics has a one year low of $0.30 and a one year high of $3.18. The stock’s fifty day moving average is $1.38 and its 200-day moving average is $1.40.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.